Nigeria’s policy reforms aimed at promoting local pharmaceutical manufacturing are beginning to show tangible results. Bayer has successfully localized production of several of its key medicines through a contract manufacturing partnership with Fidson Healthcare Plc, one of Nigeria’s leading indigenous pharmaceutical companies.

This milestone reflects a growing shift away from the country’s long-standing reliance on imported medicines, which has historically accounted for over 70 percent of pharmaceutical consumption. By leveraging local capacity, Bayer and Fidson are setting an example of how global and domestic firms can collaborate to strengthen Nigeria’s healthcare supply chain.

The Guardian contacted Yusuf Olanlokun, the supply chain professional who led the localization and technology transfer project for Bayer in Nigeria, to better understand the motivations behind the initiative.

When asked why Bayer chose to manufacture through a third party, Olanlokun explained that the decision aligned with the company’s medium-term strategy to localize the production of medicines it had already registered and promoted in Nigeria. “The move was strategic for the business but also reflected Nigeria’s evolving policy landscape,” he said.

A major catalyst was the NAFDAC Five Plus Five Policy, which requires multinational pharmaceutical companies to present clear roadmaps for local manufacturing or technology transfer within five years of product registration, with an additional five years for full implementation. Combined with government measures such as tariff reductions on pharmaceutical raw materials, the policy provided the incentives needed for Bayer to pursue local production through Fidson.

Olanlokun praised the enabling environment but also expressed caution about Nigeria’s ability to fully capture the benefits regionally. “While local production has proven viable in Nigeria, expanding exports to nearby African markets such as Ghana remains difficult due to trade flow barriers and regulatory misalignments across borders,” he noted.

Industry analysts suggest that unless such regional trade challenges are addressed, Nigeria’s pharmaceutical sector may struggle to extend its influence beyond domestic markets. Nevertheless, the Bayer-Fidson partnership is already being viewed as a proof of concept that Nigerian policy interventions, when enforced and aligned with corporate strategy, can reduce import dependence and build industrial capacity.

“This is a demonstration of how coherent regulation, supportive tariffs, and public-private collaboration can deliver real outcomes,” Olanlokun added. “The challenge now is to sustain momentum and expand opportunities for Nigerian-manufactured medicines, both locally and across the continent.”